American Association for Cancer Research

Translational Cancer Medicine 2010 - Europe

Translational Cancer Medicine 2010 - Europe

March 21-24, 2010
RAI Exhibition and
Convention Centre
Amsterdam, The Netherlands


PROGRAM COMMITTEE CHAIRPERSONS:
Susan E. Bates, National Cancer Institute, Bethesda, MD, USA
Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands


Translational cancer medicine happens at the interface between the lab and the clinic. It transitions basic science breakthroughs to the practice of medicine and uses clinical outcome to feed back into basic research. In order to make any advances in translational cancer medicine, there must be open lines of communication between researchers and clinicians.

Translational research is a key programmatic priority of the AACR, and this fourth conference in the Translational Cancer Medicine Conference Series was developed with this in mind. Through this series of international conferences, information on current advances in translational cancer medicine were presented and new collaborations were fostered through the open discourse essential for progress against cancer.

PROGRAM COMMITTEE:
José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain
Kapil N. Bhalla, Medical College of Georgia, Augusta, GA, USA
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway
Stephen J. Chanock, National Cancer Institute, Bethesda, MD, USA
Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom
E. G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands
John A. Foekens, Erasmus Medical Center, Rotterdam, The Netherlands
Nadia Harbeck, University of Cologne, Cologne, Germany
Toshihisa Ishikawa, RIKEN Yokohama Institute, Yokohama, Japan
J. Jack Lee, UT M. D. Anderson Cancer Center, Houston, TX, USA
Jennifer A. Low, Genentech, Inc., South San Francisco, CA, USA
Richard M. Marais, Institute of Cancer Research, London, United Kingdom
Julia A. Newton Bishop, University of Leeds, Leeds, United Kingdom
Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy
Marco A. Pierotti, National Tumor Institute, Milan, Italy
Mark J. Ratain, University of Chicago, Chicago, IL, USA
Eddie Reed, University of South Alabama, Mobile, AL, USA
Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA
Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
Laura J. van't Veer, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA
Otmar D. Wiestler, German Cancer Research Center, Heidelberg, Germany
John E.L. Wong, National University of Singapore, Singapore
John J. Wright, National Cancer Institute, Rockville, MD, USA

SCIENTIFIC REVIEW COMMITTEE:
Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands
Susan E. Bates, National Cancer Institute, Bethesda, MD, USA
Tito Fojo, National Cancer Institute-DHHS, Bethesda, MD, USA
Richard M. Marais, Institute of Cancer Research, London, United Kingdom